Immunotherapy shows promise in controlling advanced breast cancer after chemo
NCT ID NCT02411656
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 4 times
Summary
This study tested the drug pembrolizumab in 71 people with advanced inflammatory or triple-negative breast cancer that had spread or returned. Participants had already responded to chemotherapy. The goal was to see if pembrolizumab could keep the cancer from growing for at least 4 months. Results help doctors understand how well this immunotherapy works for these hard-to-treat cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a steroid shot before surgery tame leg swelling?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Green tea compound EGCG put to the test for clearer, more hydrated skin
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?
- Steroid shot or sports tape: which eases wisdom tooth pain better?
- Gene test could guide breast cancer treatment to boost survival